NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-08-31
Reading HCA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Achieve 2026 revenue near $77.25 billion: FY26 guidance $77.0B-$79.5B vs $77.25B target.
HCA Healthcare grows revenue about 5% yearly, aiming for $77.25 billion in 2026. It keeps buying back shares with a $10 billion program and pays rising dividends, now $0.78 per share. The company manages capital spending around $5.25 billion. These actions support steady profit and cash flow.
Revenue growth could slow if volumes drop or costs rise. Management changes and volatile capital allocation may hurt execution. The recent selloff shows market doubts about sustaining growth and margins.
The market prices HCA about 50% below our fair value near $840, reflecting cautious views despite 5% revenue growth expected. Our fair value is well above the Street median, showing a valuation gap we see as justified but risky.
Breaks if: Buybacks cease or fall materially below program pace
Breaks if: Capex exceeds $5.5B or falls below $5.0B materially
Dividend falls below $0.78 per share quarterly
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
HCA represents a durable compounder in the healthcare sector. The current thesis state is stable, supported by strong recent financial performance and ongoing management priorities.
The market currently prices HCA as cheap compared to its peers, with a notable expectations gap. This suggests that investors may not fully anticipate the potential for continued strong performance.
Management has shown a mixed track record in reaffirming revenue and earnings guidance, while capital expenditures remain disciplined. The near-term risk of missing guidance is low, but there is a history of misses that could impact sentiment.
The thesis hinges on management's ability to maintain guidance and execute on capital allocation priorities. Additionally, the performance of sector peers could influence HCA's momentum in the market.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. HCA's acquisition of 40 urgent care clinics strengthens its market presence. However, increased uninsured patients may pressure revenue growth and challenge guidance.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $76.5B in FY26
Maintain and deliver on 2026 revenue guidance range of $76.5B to $80B with stable operating environment and volume growth assumptions.
Overall, HCA's fundamentals and sector conditions support a stable long-term view. Not investment advice.
